Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 401–500 of 1,031
Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
Chen, S., Wang, Q., Yu, H., Capitano, M. L., Vemula, S., Nabinger, S. C., Gao, R., Yao, C., Kobayashi, M., Geng, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13542-2 · Cited by 123
Obesity-induced inflammation exacerbates clonal hematopoiesis
Pasupuleti, S. K., Ramdas, B., Burns, S. S., Palam, L. R., Kanumuri, R., Kumar, R., Pandhiri, T. R., Davé, U. P., Yellapu, N. K., Zhou, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163968 · Cited by 142
Advances in understanding the pathogenesis of acquired aplastic anaemia
Luzzatto, L., & Risitano, A. M. (2018) · British Journal of Haematology · doi:10.1111/bjh.15443 · Cited by 132
Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity
Cook, E. K., Luo, M., & Rauh, M. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.011 · Cited by 121
Takahashi, K., Wang, F., Morita, K., Yan, Y., Hu, P. C., Zhao, P., Zhar, A. A., Wu, C., Gumbs, C. E., Little, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04924-z · Cited by 131
Potus, F., Pauciulo, M. W., Cook, E. K., Zhu, N., Hsieh, A., Welch, C. L., Shen, Y., Tian, L., Lima, P., Mewburn, J. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044320 · Cited by 133
Molecular mechanisms in colitis-associated colorectal cancer
Zhou, R. W., Harpaz, N., Itzkowitz, S. H., & Parsons, R. E. (2023) · Oncogenesis · doi:10.1038/s41389-023-00492-0 · Cited by 140
Babushok, D. V., Bessler, M., & Olson, T. S. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1115041 · Cited by 126
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
Percival, M. M., Lai, C., Estey, E. H., & Hourigan, C. S. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.01.003 · Cited by 137
Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss
Wang, H., Divaris, K., Pan, B., Li, X., Lim, J., Saha, G., Barovic, M., Giannakou, D., Korostoff, J. M., Bing, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.003 · Cited by 137
Clinical Circulating Tumor DNA Testing for Precision Oncology
Kim, H., & Park, K. U. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1026 · Cited by 135
Rozhok, A. I., & DeGregori, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501713112 · Cited by 120
“Evidence for the effects of generally increased positive selection on cancer risk comes from the above-mentioned studies that reveal a greater risk for hematopoietic malignancies in aged people with clonal hematopoiesis (47, 48, 50, 51, 67).”
BackgroundHeuser, M., Heida, B., Büttner, K., Wienecke, C. P., Teich, K., Funke, C., Brandes, M., Klement, P., Liebich, A., Wichmann, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004367 · Cited by 119
“415 Favorable 29 (22) 7 (27) 22 (21) Intermediate 38 (29) 7 (27) 31 (30)”
Jan, M., Ebert, B. L., & Jaiswal, S. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.002 · Cited by 116
“For example, smoking was found to be associated with clonal hematopoiesis in the Swedish cohort[23], but it remains to be seen if this association is generalizable to other groups beyond schizophrenics.”
InfluentialTET Enzymes in the Immune System: From DNA Demethylation to Immunotherapy, Inflammation, and Cancer
López-Moyado, I. F., Ko, M., Hogan, P. G., & Rao, A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-080223-044610 · Cited by 129
Savola, P., Kelkka, T., Rajala, H. L. M., Kuuliala, A., Kuuliala, K., Eldfors, S., Ellonen, P., Lagström, S., Lepistö, M., Hannunen, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms15869 · Cited by 125
“(4) The initialization step in the amplification was 2 min instead of 30 s and the denaturation step was 20 s instead of 30 s.”
BackgroundEpigenetic Drift, Epigenetic Clocks and Cancer Risk
Zheng, S. C., Widschwendter, M., & Teschendorff, A. E. (2016) · Epigenomics · doi:10.2217/epi-2015-0017 · Cited by 118
The role of TP53 in acute myeloid leukemia: Challenges and opportunities
Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 131
“This leads to an expansion of the HSC clones carrying the favored alter- ations and comprises the basis of CH. CH has a spectrum of conse- quences, ranging from little to no physiological effect, all the way to a permissive state for overt leukemia following subsequent mutations.35,63-66 In confirmation, multiple rece…”
BackgroundEmergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia
Babushok, D. V., Perdigones, N., Perin, J. C., Olson, T. S., Ye, W., Roth, J. J., Lind, C., Cattier, C., Li, Y., Hartung, H. D., et al. (2015) · Cancer Genetics · doi:10.1016/j.cancergen.2015.01.007 · Cited by 122
“However, recent studies using WES of control populations have shown that only 2-3% of individuals and up to 10% of people over 65 years have clonal mutations; in contrast, healthy children and young adults have none or only rare and non-clonal somatic mutations[36-43].”
The Evolution of Lifespan and Age-Dependent Cancer Risk
Rozhok, A. I., & DeGregori, J. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.09.004 · Cited by 118
“Moreover, after the age of approximately 40 for humans, exponentially increasing clonality is observed in hematopoiesis, bringing about large expanded clones that are not observed early in life [15-18], and these clonal expansions have been postulated to result from enhanced selection in the aged bone marrow microenvi…”
BackgroundBiological background of the genomic variations of cf-DNA in healthy individuals
Liu, J., Chen, X., Wang, J., Zhou, S., Wang, C. L., Ye, M. Z., Wang, X. Y., Song, Y., Wang, Y., zhang, L., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy513 · Cited by 121
Bezerra, M. F., Lima, A. S., Piqué‐Borràs, M., Silveira, D. R., Coelho-Silva, J. L., Pereira‐Martins, D. A., Weinhäuser, I., Franca-Neto, P. L., Quek, L. S., Corby, A., et al. (2020) · Blood · doi:10.1182/blood.2019003339 · Cited by 122
Bewersdorf, J. P., & Zeidan, A. M. (2020) · Cells · doi:10.3390/cells9102310 · Cited by 132
“Additionally, the contribution of a pro-inflammatory environment in the bone marrow on HSC ageing and the development of myeloproliferative neoplasms and clonal hematopoiesis has been shown [24,37,38].”
BackgroundCobo, I., Tanaka, T. N., Chandra Mangalhara, K., Lana, A., Yeang, C., Han, C., Schlachetzki, J., Challcombe, J., Fixsen, B. R., Sakai, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.022 · Cited by 113
Diverse mutational landscapes in human lymphocytes
Machado, H. E., Mitchell, E., Øbro, N. F., Kübler, K., Davies, M., Leongamornlert, D., Cull, A., Maura, F., Sanders, M. A., Cagan, A. T. J., et al. (2022) · Nature · doi:10.1038/s41586-022-05072-7 · Cited by 116
Tatton‐Brown, K., Zachariou, A., Loveday, C., Renwick, A., Mahamdallie, S., Aksglæde, L., Baralle, D., Barge‐Schaapveld, D. Q. C. M., Blyth, M., Bouma, M. C., et al. (2018) · Wellcome Open Research · doi:10.12688/wellcomeopenres.14430.1 · Cited by 115
Genetic and epigenetic determinants of AML pathogenesis
Cai, S. F., & Levine, R. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.001 · Cited by 138
“This was first characterized by the detection of age-dependent nonrandom X chromosome inactivation in women [7], followed by large-scale whole-exome [8-10] or targeted sequencing [11,12] of patients who otherwise did not have any evidence of hematologic disorders.”
BackgroundClonal hematopoiesis and risk of acute myeloid leukemia
Young, A. L., Tong, R. S., Birmann, B. M., & Druley, T. E. (2019) · Haematologica · doi:10.3324/haematol.2018.215269 · Cited by 116
“51%/year.(2,3) For mutations detected at VAF <0.”
Tumor-Infiltrating Clonal Hematopoiesis
Pich, O., Bernard, E., Zagorulya, M., Rowan, A., Pospori, C., Slama, R., Encabo, H. H., O’Sullivan, J., Papazoglou, D., Anastasiou, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413361 · Cited by 134
Lewis, N. E., Petrova-Drus, K., Huet, S., Epstein-Peterson, Z. D., Gao, Q., Sigler, A. E., Baik, J., Ozkaya, N., Moskowitz, A. J., Kumar, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001636 · Cited by 114
“In addition, the CH clones often harbored $2 TET2 mutations (10 out of 15 [67%]) and/or both TET2 and DNMT3A mutations (9 out of 15 [60%]), which is more frequent than in the general population with CH (multiple mutations reported in ;5% to 15%).(11,12,24,25) The significance of CH with multiple mutations is unclear b…”
BackgroundPredictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
Issa, G. C., Zarka, J. G., Sasaki, K., Qiao, W., Pak, D., Ning, J., Short, N. J., Haddad, F., Tang, Z., Patel, K. P., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00557-6 · Cited by 126
Vlasschaert, C., McNaughton, A. J. M., Chong, M., Cook, E. K., Hopman, W., Kestenbaum, B., Robinson-Cohen, C., Garland, J., Moran, S. M., Paré, G., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021060774 · Cited by 110
“5%–1%.(9,10) CHIP also predicts risk of developing cardiovascular disease and all-cause mortality, including in people with CKD.”
BackgroundClonal hematopoiesis in patients with rheumatoid arthritis
Savola, P., Lundgren, S., Keränen, M. A. I., Almusa, H., Ellonen, P., Leirisalo-Repo, M., Kelkka, T., & Mustjoki, S. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0107-2 · Cited by 112
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana, M., Six, E., Lagresle-Peyrou, C., André-Schmutz, I., & Hacein-Bey-Abina, S. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.137 · Cited by 106
“76 Given (1) the current inability to predict adverse events (despite intense work on RIS analysis) and (2) the absence of an accurate animal or in vitro model of toxicity, the continuous clinical follow-up of the patients is the only way to monitor the safety and efficacy of new vector designs and…”
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 119
Insights into variation in meiosis from 31,228 human sperm genomes
Bell, A. D., Mello, C. J., Nemesh, J. C., Brumbaugh, S. A., Wysoker, A., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2347-0 · Cited by 118
Self-citationBhattacharya, R., Zekavat, S. M., Uddin, M. M., Pirruccello, J., Niroula, A., Gibson, C., Griffin, G. K., Libby, P., Ebert, B. L., Bick, A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1678 · Cited by 109
Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis
Weinstock, J. S., Gopakumar, J., Burugula, B. B., Uddin, M. M., Jahn, N., Belk, J. A., Bouzid, H., Daniel, B., Miao, Z., Ly, N., et al. (2023) · Nature · doi:10.1038/s41586-023-05806-1 · Cited by 118
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
Dao, J., Conway, P., Subramani, B., Meyyappan, D., Russell, S., & Mahadevan, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713219 · Cited by 121
“One challenge that was previously a concern was the lower specificity of detecting ctDNA due to CHIP, which are mutations associated with myeloid cancers and frequently mutated in healthy patients [151].”
BackgroundClonal Hematopoiesis of Indeterminate Potential
Heuser, M., Thol, F. R., & Ganser, A. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0317 · Cited by 135
“Of the patients with CHIP who showed a malignant hematologic disease, about 60% had a my eloid neoplasm (AML, MDS, chronic myelomonocytic leukemia [CMML], myeloproliferative neoplasm [MPN]) and about 40% a lymphoid neoplasm (chronic lymphocytic leukemia [CLL], multiple myeloma, B-cell lymphoma) (8).”
BackgroundInfluentialA clinician’s handbook for using ctDNA throughout the patient journey
Hasenleithner, S. O., & Speicher, M. R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01551-7 · Cited by 116
CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors
Reed, S. C., Croessmann, S., & Park, B. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2598 · Cited by 118
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
Semenkovich, N. P., Szymanski, J. J., Earland, N. J., Chauhan, P. S., Pellini, B., & Chaudhuri, A. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006284 · Cited by 125
Groarke, E. M., & Young, N. S. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.03.001 · Cited by 119
Myelodysplastic syndromes: moving towards personalized management
Hellström‐Lindberg, E., Tobiasson, M., & Greenberg, P. L. (2020) · Haematologica · doi:10.3324/haematol.2020.248955 · Cited by 117
“, DNMT3A, TET2 and ASXL1, are also found in healthy individuals (clonal hematopoiesis of indeterminate prognosis, CHIP), representing pre-leukemic clones with an ageassociated incidence and a varying risk of subsequent development of MDS or other myeloid malignancies.(26,27) Several of the recurrently mutated genes ar…”
BackgroundThe Hematopoietic Bone Marrow Niche Ecosystem
Fröbel, J., Landspersky, T., Perçin, G. I., Schreck, C., Rahmig, S., Ori, A., Nowak, D., Essers, M. A. G., Waskow, C., & Oostendorp, R. A. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705410 · Cited by 122
Tulstrup, M., Soerensen, M., Hansen, J. W., Gillberg, L., Needhamsen, M., Kaastrup, K., Helin, K., Christensen, K., Weischenfeldt, J., & Grønbæk, K. (2021) · Nature Communications · doi:10.1038/s41467-021-26093-2 · Cited by 108
Debarri, H., Lebon, D., Roumier, C., Cheok, M. H.-C., Marceau‐Renaut, A., Nibourel, O., Geffroy, S., Hélevaut, N., Rousselot, P. H., Gruson, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5645 · Cited by 118
“reported that the frequency of mutations among individuals older than 65 years was 10% and that the most frequent mutations affected DNMT3A gene [23].”
BackgroundWong, T. N., Miller, C. A., Klco, J. M., Petti, A., Demeter, R., Helton, N. M., Li, T., Fulton, R. S., Heath, S. E., Mardis, E. R., et al. (2016) · Blood · doi:10.1182/blood-2015-10-677021 · Cited by 108
“Clonal hematopoiesis of indeterminate potential in healthy adults is typically identified in elderly individuals, and the clonal population often remains stable (or expands slowly) over multiple years.(14-16) In contrast, patients with a rising clone following induction therapy were relatively younger and exhibited a…”
BackgroundMutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 118
“4% individuals aged over 65 years to 108 years [115-117].”
BackgroundInfluentialDynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Uy, G. L., Duncavage, E. J., Chang, G. S., Jacoby, M. A., Miller, C. A., Shao, J., Heath, S., Elliott, K., Reineck, T., Fulton, R. S., et al. (2017) · Leukemia · doi:10.1038/leu.2016.282 · Cited by 104
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Grinfeld, J., Nangalia, J., & Green, A. R. (2016) · Haematologica · doi:10.3324/haematol.2014.113845 · Cited by 117
Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer
Phallen, J. A., Leal, A., Woodward, B. D., Forde, P. M., Naidoo, J., Marrone, K. A., Brahmer, J. R., Fiksel, J., Medina, J. E., Cristiano, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1082 · Cited by 118
Fujino, T., Goyama, S., Sugiura, Y., Inoue, D., Asada, S., Yamasaki, S., Matsumoto, A., Yamaguchi, K., Isobe, Y., Tsuchiya, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22053-y · Cited by 103
Clonal hematopoiesis, somatic mosaicism, and age-associated disease
Evans, M. A., & Walsh, K. X. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2022 · Cited by 116
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
Dharan, N. J., Yeh, P., Bloch, M., Yeung, M. M., Baker, D., Guinto, J., Roth, N., Ftouni, S., Ognenovska, K., Smith, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01357-y · Cited by 108
Bohers, É., Viailly, P., Becker, S., Marchand, V., Ruminy, P., Maingonnat, C., Bertrand, P., Etancelin, P., Picquenot, J., Camus, V., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0111-6 · Cited by 116
TET family dioxygenases and the TET activator vitamin C in immune responses and cancer
Yue, X., & Rao, A. (2020) · Blood · doi:10.1182/blood.2019004158 · Cited by 103
Splicing factor mutations in hematologic malignancies
Chen, S., Benbarche, S., & Abdel-Wahab, O. I. (2021) · Blood · doi:10.1182/blood.2019004260 · Cited by 119
Relationship between clone metrics and clinical outcome in clonal cytopenia
Gallì, A., Todisco, G., Catamo, E., Sala, C., Elena, C., Pozzi, S., Bono, E., Ferretti, V. V., Rizzo, E., Molteni, E., et al. (2021) · Blood · doi:10.1182/blood.2021011323 · Cited by 104
“BM blasts, %, median (range) — — 2 (1-3) 2 (1-98)”
Rouhani, F. J., Zou, X., Danecek, P., Badja, C., Amarante, T. D., Koh, G., Wu, Q., Memari, Y., Durbin, R., Martincorena, I., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01147-3 · Cited by 105
Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications
Yang, X., Wong, M. P. M., & Ng, R. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184576 · Cited by 141
“Since DNMT3A and TET2 mutations can prime HSCs to a pre-leukemic state through dysregulation of DNA methylation [51,52], it is proposed that assessing the aberrant DNA methylation pattern is valuable for an early detection of AML with no clinical manifestations.”
BackgroundPrinciples of the Molecular and Cellular Mechanisms of Aging
da Silva, P. F. L., & Schumacher, B. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.018 · Cited by 100
Bone Marrow Niches of Hematopoietic Stem and Progenitor Cells
Kandarakov, O. F., Belyavsky, A. V., & Semenova, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084462 · Cited by 116
“Accumulation of mutations in epigenetic regulator genes in HSCs with age leads to clonal hematopoiesis, enhanced inflammation and increased risk of cardiovascular diseases and malignancies [181,182].”
BackgroundMechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease
Narayan, V., Thompson, E. W., Demissei, B., Ho, J. E., Januzzi, J. L., & Ky, B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.067 · Cited by 103
“In addition to age, apparent risk factors for CHIP include male sex, cigarette smoking, and a germline polymorphism in TERT, a gene encoding a component of the telomerase complex.(99, 100)”
BackgroundClonal hematopoiesis and associated diseases: A review of recent findings
Asada, S., & Kitamura, T. (2021) · Cancer Science · doi:10.1111/cas.15094 · Cited by 111
Kasi, P. M., Fehringer, G., Taniguchi, H., Starling, N., Nakamura, Y., Kotani, D., Powles, T. B., Li, B. T., Pusztai, L., Aushev, V. N., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00181 · Cited by 118
“Tie et al(69) Colon cancer stage III Postoperative (4-10 weeks; N = 96); at completion of treatment (n = 88) Safe-SeqS Fifteen CRC genes assessed in tumor; in plasma used the variant with the highest allele frequency (tumor-informed) Median: 51 (9-470) days Median: 28.”
BackgroundMethodNair, N., Camacho-Vanegas, O., Rykunov, D., Dashkoff, M., Camacho, S. C., Schumacher, C. A., Irish, J. C., Harkins, T. T., Freeman, E., Garcia, I., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002206 · Cited by 99
“Results from three nearly back-to-back whole-exome [58,59] and gene panel targeted sequencing studies [60] on nearly 34,000 individuals identified clonal hematopoiesis with leukemia-related, somatic driver mutations, most notably DNMT3A, in 10% of apparently healthy individuals >65 years of age and in nearly 20% in th…”
BackgroundKunimoto, H., Meydan, C., Nazir, A., Whitfield, J., Shank, K., Rapaport, F., Maher, R., Pronier, E., Meyer, S. C., Garrett-Bakelman, F. E., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.11.012 · Cited by 98
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications
Valent, P. (2018) · Pathobiology · doi:10.1159/000489042 · Cited by 119
Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis
de Andrade, K. C., Frone, M. N., Wegman-Ostrosky, T., Khincha, P. P., Kim, J., Amadou, A., Santiago, K. M., Fortes, F. P., Lemonnier, N., Mirabello, L., et al. (2019) · Human Mutation · doi:10.1002/humu.23673 · Cited by 99
MDS overlap disorders and diagnostic boundaries
Tanaka, T. N., & Bejar, R. L. (2019) · Blood · doi:10.1182/blood-2018-10-844670 · Cited by 107
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice
DeZern, A. E., Malcovati, L., & Ebert, B. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239083 · Cited by 98
Hecker, J. S., Hartmann, L., Rivière, J., Buck, M. C., van der Garde, M., Rothenberg-Thurley, M., Fischer, L., Winter, S., Ksienzyk, B., Ziemann, F., et al. (2021) · Blood · doi:10.1182/blood.2020010163 · Cited by 105
“Genome-wide or targeted sequencing revealed an ageing-associated increase of clonal hematopoiesis (CH) in healthy individuals 2 – 6 .”
Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells
Itokawa, N., Oshima, M., Koide, S., Takayama, N., Kuribayashi, W., Nakajima‐Takagi, Y., Aoyama, K., Yamazaki, S., Yamaguchi, K., Furukawa, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30440-2 · Cited by 110
Loss of Y Chromosome in Peripheral Blood of Colorectal and Prostate Cancer Patients
Noveski, P., Madjunkova, S., Sukarova Stefanovska, E., Matevska Geshkovska, N., Kuzmanovska, M., Dimovski, A., & Plaseska-Karanfilska, D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146264 · Cited by 102
“Recently, clonal hematopoiesis with somatic mutations was shown not only to be increasingly common in elderly people but also to increase the risk of hematological malignancies and death [36,37], with the possibility that all-cause mortality is due to an increased risk of cardiovascular disease [36].”
BackgroundSasaki, K., Kanagal‐Shamanna, R., Montalban‐Bravo, G., Assi, R., Jabbour, E., Ravandi, F., Kadia, T., Pierce, S., Takahashi, K., Nogueras Gonzalez, G., et al. (2020) · Cancer · doi:10.1002/cncr.32566 · Cited by 101
“Median percentage of blasts in bone marrow (range) 44 (1-96) 40 (1-95) 50 (1-96) .”
BackgroundInfluentialAged hematopoietic stem cells are refractory to bloodborne systemic rejuvenation interventions
Ho, T. T., Dellorusso, P. V., Verovskaya, E. V., Bakker, S. T., Flach, J., Smith, L. K., Ventura, P. B., Lansinger, O. M., Hérault, A., Zhang, S. Y., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20210223 · Cited by 101
Meyer, S. E., Qin, T., Muench, D. E., Masuda, K., Venkatasubramanian, M., Orr, E., Suarez, L., Gore, S. D., Delwel, R., Paietta, E., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0008 · Cited by 101
Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones
de Boer, B., Prick, J. C. M., Pruis, M. G. M., Keane, P., Imperato, M. R., Jaques, J., Brouwers-Vos, A. Z., Hogeling, S. M., Woolthuis, C. M., Nijk, M. T., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.014 · Cited by 106
“, DNMT3A, ASXL1, and TET2) frequently occur in the healthy elderly, resulting in clonal hematopoiesis without overt hematological malignant phenotypes, further highlighting that these lesions are insufficient to induce disease on their own (Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).”
BackgroundSalk, J. J., Loubet-Senear, K., Maritschnegg, E., Valentine, C. C., Williams, L. N., Higgins, J. E., Horvat, R., Vanderstichele, A., Nachmanson, D., Baker, K. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.109 · Cited by 95
“In addition, specificity could likely be improved by uniform lavage collection at the luteal phase in premenopausal women, sequencing of peripheral blood to identify and exclude CHIP clones that may be present in lavage, and longitudinal assessment of mutations to identify MAF increases over time.”
BackgroundInfluentialUddin, M. M., Nguyen, N. Q., Yu, B., Brody, J. A., Pampana, A., Nakao, T., Fornage, M., Bressler, J., Sotoodehnia, N., Weinstock, J. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33093-3 · Cited by 106
Analysis of cancer genomes reveals basic features of human aging and its role in cancer development
Podolskiy, D. I., Lobanov, A. V., Kryukov, G. V., & Gladyshev, V. N. (2016) · Nature Communications · doi:10.1038/ncomms12157 · Cited by 100
“This non-linear accumulation of somatic mutations with age is also consistent with recent estimations of the behaviour of mutation load with age in hematopoietic clones 16,17 .”
Driver mutations in acute myeloid leukemia
Kishtagari, A., Levine, R. L., & Viny, A. D. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000567 · Cited by 113
Telomeres and Age-Related Diseases
Gruber, H.-J., Semeraro, M. D., Renner, W., & Herrmann, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101335 · Cited by 94
Fioredda, F., Skokowa, J., Tamary, H., Spanoudakis, M., Farruggia, P., Almeida, A. M., Guardo, D., Höglund, P., Newburger, P. E., Palmblad, J. E. W., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000872 · Cited by 120
Arends, C. M., Liman, T. G., Strzelecka, P. M., Kufner, A., Löwe, P., Huo, S., Stein, C. M., Piper, S. K., Tilgner, M., Sperber, P. S., et al. (2023) · Blood · doi:10.1182/blood.2022017661 · Cited by 99
Clonal hematopoiesis and risk for hematologic malignancy
Warren, J. T., & Link, D. C. (2020) · Blood · doi:10.1182/blood.2019000991 · Cited by 28
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy
Serrano, M. J., Garrido-Navas, M. C., Díaz‐Mochon, J. J., Cristofanilli, M., Bazo, I. G., Pauwels, P., Malapelle, U., Russo, A., Lorente, J. A., Ruiz-Rodríguez, A. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0466 · Cited by 102
“However, in a recent study, Genovese and colleagues sequenced the cfDNA of 12,380 individuals, unselected for cancer or hematologic phenotypes, for mutations, with follow-ups for 2 to 7 years (39).”
MethodAt the dawn: cell-free DNA fragmentomics and gene regulation
Liu, Y. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01635-z · Cited by 111
Lee, L. H., Gasilina, A., Roychoudhury, J., Clark, J. P., McCormack, F. X., Pressey, J. G., Grimley, M. S., Lorsbach, R. B., Ali, S. M., Bailey, M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89473 · Cited by 101
“Many of these identified mutations occur in adult patients, and involve genes implicated in the recently described phenomenon clonal hematopoiesis of indeterminate potential (CHIP) such as DNMT3A, TET2, and ASXL1 (29, 30).”
BackgroundAcute myeloid leukaemia genomics
Medinger, M., & Passweg, J. R. (2017) · British Journal of Haematology · doi:10.1111/bjh.14823 · Cited by 110
Tóthová, Z., Krill-Burger, J. M., Popova, K. D., Landers, C. C., Sievers, Q. L., Yudovich, D., Belizaire, R., Aster, J. C., Morgan, E. A., Tsherniak, A., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.015 · Cited by 110
Wnt activity and basal niche position sensitize intestinal stem and progenitor cells to DNA damage
Tao, S., Tang, D., Morita, Y., Sperka, T., Omrani, O., Lechel, A., Sakk, V., Kraus, J., Kestler, H. A., Kühl, M., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490700 · Cited by 95
“Emerging data indicate that adult tissue stem cells accumulate mutations that contribute to cancer initiation during aging (Busque et al , 2012; Jan et al , 2012; Welch et al , 2012; Genovese et al , 2014; Jaiswal et al , 2014; Xie et al , 2014).”
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
Neuendorff, N. R., Burmeister, T., Dörken, B., & Westermann, J. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2721-z · Cited by 107
“There is increasing evidence that the presence of agedependent clonal hematopoiesis is a risk factor for the development of hematological malignancies [12, 13].”
BackgroundClonality in context: hematopoietic clones in their marrow environment
Cooper, J. N., & Young, N. S. (2017) · Blood · doi:10.1182/blood-2017-07-794362 · Cited by 87
“Explicit analogies to conditions with low rates of malignant progression, such as monoclonal gammopathy of unknown significance (MGUS) or monoclonal B-cell lymphocytosis, were intended to alleviate concerns that detection of CHIP signified that an individual was destined to develop MDS/AML.”
BackgroundInfluentialNew Insights from Studies of Clonal Hematopoiesis
Gibson, C. J., & Steensma, D. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3044 · Cited by 100
“Two of those studies were exome sequencing efforts aimed at identifying germline risk variants for diabetes (13) and schizophrenia (14), whereas a third included control blood samples paired with exome sequencing of solid tumors performed for The Cancer Genome Atlas (12).”
BackgroundMethodInfluentialDivergent Effects of Dnmt3a and Tet2 Mutations on Hematopoietic Progenitor Cell Fitness
Ostrander, E. L., Kramer, A. C., Mallaney, C., Celik, H., Koh, W. K., Fairchild, J., Haussler, E., Zhang, C. R. C., & Challen, G. A. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.02.011 · Cited by 94
“In addition, variants in DNMT3A and TET2 are the most prevalent events associated with clonal hematopoiesis (CH), where pathogenic mutations are found in the blood of elderly people lacking overt disease (Buscarlet et al., 2017; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).”
BackgroundOrgan System Crosstalk in Cardiometabolic Disease in the Age of Multimorbidity
Oishi, Y., & Manabe, I. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00064 · Cited by 101
“However, these individuals have an approximately 10-fold greater risk for hematologic cancer than the general population, suggesting that CHIP may represent a premalignant state (94).”
BackgroundEpigenetic Regulators as the Gatekeepers of Hematopoiesis
Rodrigues, C. P., Shvedunova, M., & Akhtar, A. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.09.015 · Cited by 107
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.